Who Exports Emtricitabine from India — 141 Suppliers Behind a $119.4M Market
India's emtricitabine export market is supplied by 141 active exporters who collectively shipped $119.4M across 2,194 shipments. MYLAN LABORATORIES LIMITED leads with a 35.6% market share, followed by MACLEODS PHARMACEUTICALS LTD and AUROBINDO PHARMA LTD. The top 5 suppliers together control 83.6% of total export value, reflecting a concentrated market structure.
Top Emtricitabine Exporters from India — Ranked by Export Value
MYLAN LABORATORIES LIMITED is the leading emtricitabine exporter from India, holding a 35.6% share of the $119.4M market across 2,194 shipments from 141 exporters. The top 5 suppliers — MYLAN LABORATORIES LIMITED, MACLEODS PHARMACEUTICALS LTD, AUROBINDO PHARMA LTD, LUPIN LIMITED, CIPLA LIMITED — collectively control 83.6% of total export value, indicating a highly concentrated market. Individual shares are: MYLAN LABORATORIES LIMITED (35.6%), MACLEODS PHARMACEUTICALS LTD (32.8%), AUROBINDO PHARMA LTD (6.4%), LUPIN LIMITED (5.2%), CIPLA LIMITED (3.8%).
Top Emtricitabine Exporters from India
Ranked by export value · 141 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $42.5M | 53 | 35.6% |
| 2 | MACLEODS PHARMACEUTICALS LTD ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $39.1M | 34 | 32.8% |
| 3 | AUROBINDO PHARMA LTD ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $7.6M | 9 | 6.4% |
| 4 | LUPIN LIMITED EMTRICITABINE 200MG+TENOFOVIR DISOPROXIL | $6.2M | 4 | 5.2% |
| 5 | CIPLA LIMITED TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINEEMTRICITABINE CAPSULES 200MG NDC NO. 6 | $4.5M | 10 | 3.8% |
| 6 | HETERO LABS LIMITED EMTRICITABINE AND TENOFOVIR DISOPROXIL FMEDICINES. EMTRICITABINE 200MG + TENOFOVTENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINE | $4.4M | 26 | 3.7% |
| 7 | MACLEODS PHARMACEUTICALS LIMITED ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $4.2M | 19 | 3.5% |
| 8 | AUROBINDO PHARMA LIMITED ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $3.5M | 6 | 3.0% |
| 9 | STRIDES PHARMA SCIENCE LIMITED | $1.6M | 6 | 1.3% |
| 10 | EMCURE PHARMACEUTICALS LIMITED ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $1.5M | 20 | 1.2% |
| 11 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $873.0K | 3 | 0.7% |
| 12 | LAURUS LABS LIMITED TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINEEMTRICITABINE CAPSULES 200MG NDC NO. 6 | $686.7K | 6 | 0.6% |
| 13 | LAURUS LABS PRIVATE LIMITED TENOFOVIR DISOPROXIL FUMARATE + EMTRICITABINEEMTRICITABINE CAPSULES 200MG NDC NO. 6 | $535.0K | 4 | 0.4% |
| 14 | DELTA BIOPHARMA PRIVATE LIMITED | $227.9K | 2 | 0.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Emtricitabine exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Aurobindo Pharma Limited | Warning Letter, January 2 | Yes, multiple produc | Unknown | Multiple, including Emtricitabine Capsules 200mg | Received FDA warning letter in January 2022 for CGMP deviations; WHO prequalifie |
| Mylan Laboratories Limited | Approved | Yes, multiple produc | Unknown | Multiple, including Emtricitabine/Tenofovir alafenamide Tablet 200mg/25mg | WHO prequalified Emtricitabine/Tenofovir alafenamide tablets; no FDA warning let |
| Macleods Pharmaceuticals Ltd | Approved | Yes, multiple produc | Unknown | Multiple, including Emtricitabine/Tenofovir disoproxil fumarate Tablet 200mg/300mg | WHO prequalified Emtricitabine/Tenofovir disoproxil fumarate tablets; no FDA war |
| Lupin Limited | Approved | Yes, multiple produc | Unknown | Multiple | WHO prequalified Moxifloxacin and Atazanavir/Ritonavir tablets; no FDA warning l |
| Hetero Labs Limited | Approved | Yes, multiple produc | Unknown | Multiple | WHO prequalified Dolutegravir/Lamivudine/Tenofovir disoproxil fumarate tablets; |
| Strides Pharma Science Limited | Approved | Yes, multiple produc | Unknown | Multiple | WHO prequalified Emtricitabine/Tenofovir disoproxil fumarate tablets; no FDA war |
| Emcure Pharmaceuticals Limited | Approved | Yes, multiple produc | Unknown | Multiple | WHO prequalified Dolutegravir and Dolutegravir/Lamivudine/Tenofovir disoproxil f |
| Laurus Labs Limited | Approved | Yes, multiple produc | Unknown | Multiple | WHO prequalified Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate tablets; |
TransData Nexus reviewed the regulatory standing of 8 leading Emtricitabine exporters from India. 7 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 0 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Emtricitabine sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes approximately 40% of the country's bulk drug production. The city hosts over 2,000 pharmaceutical companies, including major players like Aurobindo Pharma Ltd and Dr. Reddy’s Laboratories. The establishment of Genome Valley, a premier biotech cluster, has further solidified Hyderabad's position as a global hub for pharmaceutical manufacturing and research.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations. Gujarat accounts for 33% of India's drug manufacturing and 28% of drug exports. Vadodara, in particular, is home to Alembic Pharmaceuticals, one of India's oldest pharmaceutical companies, established in 1907. The region's robust infrastructure and skilled workforce have attracted numerous pharmaceutical companies, making it a significant hub for drug formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates the export of pharmaceutical products to various international markets. The region hosts several pharmaceutical companies, including Cipla Limited, which has a notable share in Emtricitabine exports. The strategic location and well-developed logistics infrastructure make this cluster pivotal for the distribution of pharmaceutical products globally.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a prominent pharmaceutical hub, primarily due to favorable tax incentives offered by the government. The region has attracted numerous pharmaceutical companies, contributing significantly to India's drug manufacturing capacity. The tax benefits and supportive policies have made Baddi-Nalagarh an attractive destination for pharmaceutical investments.
5Sourcing Recommendations
- Diversify Supplier Base: Given the concentration of Emtricitabine exports among a few suppliers, it's advisable to diversify the supplier base to mitigate risks associated with over-reliance on a limited number of exporters.
- Leverage Regional Strengths: Utilize the bulk drug manufacturing capabilities of Hyderabad and the formulation expertise of the Ahmedabad-Vadodara corridor to optimize the supply chain for Emtricitabine.
- Enhance Export Logistics: Capitalize on the export infrastructure of the Mumbai-Thane-Raigad region to ensure efficient distribution of Emtricitabine to international markets.
- Monitor Policy Changes: Stay informed about tax incentives and regulatory changes in regions like Baddi-Nalagarh to take advantage of cost-saving opportunities in pharmaceutical manufacturing.
By strategically engaging with these pharmaceutical clusters and implementing the above recommendations, stakeholders can enhance the efficiency and resilience of the Emtricitabine supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Emtricitabine exporters from India
Lupin Limited — Lupin acquires French pharmaceutical company Medisol
In May 2023, Lupin Limited announced the acquisition of Medisol, a French pharmaceutical company, aiming to strengthen its presence in the European market. - IMPACT: This acquisition is expected to enhance Lupin's distribution network in Europe, potentially increasing Emtricitabine exports to the region.
Impact: This acquisition is expected to enhance Lupin's distribution network in Europe, potentially increasing Emtricitabine exports to the region.
Aurobindo Pharma Limited — Aurobindo's TheraNym Biologics partners with Merck for biologics manufacturing
In May 2024, TheraNym Biologics, a wholly owned subsidiary of Aurobindo Pharma, signed an agreement with Merck & Co. to expand its biologics manufacturing facilities and explore contract manufacturing operations for biologics. - IMPACT: This collaboration may lead to increased production capabilities, potentially boosting Emtricitabine exports.
Impact: This collaboration may lead to increased production capabilities, potentially boosting Emtricitabine exports.
Cipla Limited — Cipla receives US FDA approval for Glucagon ANDA
In September 2025, Cipla Limited received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Glucagon, expanding its product portfolio in the US market. - IMPACT: This approval may enhance Cipla's market presence in the US, potentially leading to increased Emtricitabine exports.
Impact: This approval may enhance Cipla's market presence in the US, potentially leading to increased Emtricitabine exports.
Common Questions — Emtricitabine Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which emtricitabine supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MYLAN LABORATORIES LIMITED leads with 265 recorded shipments worth $42.5M. MACLEODS PHARMACEUTICALS LTD (280 shipments) and AUROBINDO PHARMA LTD (118 shipments) are also established high-volume exporters.
Q How many emtricitabine manufacturers are there in India?
India has 141 active emtricitabine exporters with a combined export market of $119.4M across 2,194 shipments to 117 countries. The top 5 suppliers hold 83.6% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for emtricitabine from India?
Average FOB unit price: $11.21 per unit, ranging from $0.00 to $1153.61. Average shipment value: $54.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 141 verified Indian exporters of Emtricitabine ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,194 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 117 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,194 Verified Shipments
141 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists